Effect of nandrolone decanonate on paraoxonase activity in hemodialysis patients

Clinical Biochemistry

Volumn 38, Issue 12, 2005, Pages 1076-1080

  Ghorbanihaghjo, Amir ^a   Argani, Hassan ^a   Rahbaninoubar, Mohammad ^a   Rashtchizadeh, Nadereh ^a  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Apolipoprotein A I; Apolipoprotein B; Hemodialysis; Nandrolone decanoate; Paraoxonase

Indexed keywords

APOLIPOPROTEIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ARYLDIALKYLPHOSPHATASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; NANDROLONE DECANOATE;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME ACTIVITY; FEMALE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

APOLIPOPROTEIN A-I; APOLIPOPROTEINS B; ARYLDIALKYLPHOSPHATASE; CHOLESTEROL, HDL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; FEMALE; HUMANS; MALE; MIDDLE AGED; NANDROLONE; RENAL DIALYSIS; SENSITIVITY AND SPECIFICITY; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 29144494885     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2005.08.006     Document Type: Article

References (37)

1. K. Kalantar-Zadeh, T.A. Ikizler, G. Block, M.M. Avram, and J.D. Kopple Malnutrition-inflammation complex syndrome in dialysis patients: causes and consequences Am. J. Kidney Dis. 42 2003 864 881
2. R.N. Foley, P.S. Parfrey, and J.D. Harnett The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease Am. J. Kidney Dis. 28 1996 53 61
3. M. Bonomini, and V. Sirolli Uremic toxicity and anemia J. Nephrol. 16 2003 21 28
4. C. Level, C. Lasseur, and Y. Delmas Determinants of arterial compliance in patients treated by hemodialysis Clin. Nephrol. 56 2001 435 444
5. S. Li, and A.J. Collins Association of hematocrit value with cardiovascular morbidity and mortality in incident hemodialysis patients Kidney Int. 65 2004 626 633
6. M.M. Prata, C. Madeira, O. Vicente, and M.J. Miguel Lipid profile in haemodialysis patients treated with recombinant human erythropoietin Nephrol. Dial. Transplant. 13 9 1998 2345 2347
7. K.L. Johansen, K. Mulligan, and M. Schambelan Anabolic effect on nandrolone decanoate in patients receiving dialysis: a randomized controlled trial JAMA 281 1999 1275 1281
8. C.T. Chab Cardiovascular effect of frequent intensive hemodialysis Semin. Dial. 17 2004 99 103
9. J.L. Teruel, M.A. Lasuncion, and M. Rivera Nandrolone decanoate reduces serum lipoprotein (a) concentrations in hemodialysis patients Am. J. Kidney Dis. 29 1997 569 575
10. A. Santoro Anemia in renal insufficiency Rev. Clin. Exp. Hematol. 1 2002 12 20
11. C.G. Winearls Recombinant human erythropoietin: 10 years of clinical experience Nephrol. Dial. Transplant. 13 1998 3 8
12. M. Inal, G. Kanbak, S. Sen, F. Akyuz, and E. Sunal Antioxidant status and lipid peroxidation in hemodialysis patients undergoing erythropoietin and erythropoietin-vitamin E combined therapy Free Radic. Res. 31 1999 211 216
13. D. Paskalev, T. Jankova, P. Tschankova, M. Stiner, and D. Nenov Increase of plasma and red blood cell vitamin E concentration in uraemic patients on maintenance haemodialysis undergoing treatment with recombinant erythropoietin Nephrol. Dial. Transplant. 8 1993 1187 1188
14. J.F. Navarro In the erythropoietin era, can we forget alternative or adjunctive therapies for renal anaemia management? The androgen example Nephrol. Dial. Transplant. 18 2003 2222 2226
15. A. Gascon, J.J. Belvis, F. Berisa, E. Iglesias, V. Estopinan, and J.L. Teruel Nandrolone decanoate is a good alternative for the treatment of anemia in elderly male patients on hemodialysis Geriatr. Nephrol. Urol. 9 1999 67 72
16. S. Matnur, S. Devaraj, and I. Jialal Accelerated atherosclerosis, dislipidemia, and oxidative stress in end-stage renal disease Curr. Opin. Nephrol. Hypertens. 11 2002 141 147
17. C. Wanner, J. Zimmermann, T. Quaschning, and J. Galle Inflammation, dyslipidemia and vascular risk factors in hemodialysis patients Kidney Int. Suppl. 62 1997 S53 S55
18. M. Morena, J.P. Cristol, T. Dantoine, M.A. Carbonneau, B. Descomps, and B. Canaud Protective effects of high-density lipoprotein against oxidative stress are impaired in haemodialysis patients Nephrol. Dial. Transplant. 15 2000 389 395
19. D.M. Lee, C. Knight-Gibson, O. Samuelsson, P.O. Attman, C.S. Wang, and P. Aaupovic Lipoprotein particle abnormalities and the impaired lipolysis in renal insufficiency Kidney Int. 6 2002 209 218
20. J.P. Cristol, J.Y. Bosc, and S. Badiou Erythropoietin and oxidative stress in haemodialysis: beneficial effects of vitamin E supplementation Nephrol. Dial. Transplant. 12 1997 2312 2317
21. M. Boaz, Z. Matas, and A. Biro Serum malondialdehyde and prevalent cardiovascular disease in hemodialysis Kidney Int. 56 1999 1078 1083
22. J. Drai, E. Bannier, and C. Chazot Oxidants and antioxidants in long-term haemodialysis patients Farmaco 56 2001 463 465
23. H.H. Jung, D.H. Choi, and S.H. Lee Serum malondialdehyde and coronary artery disease in hemodialysis patients Am. J. Nephrol. 24 2004 537 542
24. C.A. Johnson Use of androgens in patients with renal failure Semin. Dial. 13 2000 36 39
25. A. Barton Pai, C. Chretien, and A.H. Lau The effect of nandrolone decanoate on nutritional parameters in hemodialysis patients Clin. Nephrol. 58 2002 38 46
26. G. Paragh, L. Asztalos, and I. Seres Serum paraoxonase activity changes in uremic and kidney-transplanted patients Nephron 83 1999 126 131
27. K. Satoh Serum lipid peroxide in cerebrovascular disorders determined by a new colorimetric method Clin. Chim. Acta 90 1978 37 43
28. A. Gorbanihaghjo, H. Argani, M. Rohbaninoubar, and N. Rashtchizadeh Effect of nandrolone decanoate on serum lipoprotein (a) and its isoforms in hemodialysis patients Lipids Health Dis. 3 2004 16
29. E. Ritz Atherosclerosis in dialyzed patients Blood Purif. 22 2004 28 37
30. G. Walldius, and I. Jungner Apolipoprotein B and apolipoprotein A-I: risk indicators of coronary heart disease and targets for lipid-modifying therapy J. Intern. Med. 255 2004 188 205
31. M. Usberti, G.M. Gerardi, and R.M. Gazzotti Oxidative stress and cardiovascular disease in dialyzed patients Nephron 91 2002 25 33
32. R.S. Munford Statins and the acute phase response N. Engl. J. Med. 344 2001 2016 2018
33. H. Argani, A. Ghorbani, N. Rashtchizadeh, and M. Rahbaninobar Effect of lovastatin on lipid peroxidation and total antioxidant concentration in hemodialysis patients Lipids Health Dis. 3 2004 6
34. H. Trimarchi, M.R. Mongitore, and P. Baglioni N-acetylcysteine reduces malondialdehyde levels in chronic hemodialysis patients-A pilot study Clin. Nephrol. 59 2003 441 446
35. A. Kondo, J. Li, M. Manabe, K. Saito, T. Kanno, and M. Maekawa Relationship between high-density lipoprotein-cholesterol and malondialdehyde-modified low-density lipoprotein concentrations J. Atheroscler. Thromb. 10 2003 72 78
36. A.N. Klimov, V.S. Gurevich, and A.A. Nikiforova Antioxidative activity of high density lipoproteins in vivo Atherosclerosis 100 1993 13 18
37. M. Tomas, M. Senti, and F. Garcia-Faria Effect of simvastatin therapy on paraoxonase activity and related lipoproteins in familial hypercholesterolemic patients Arterioscler. Thromb. Vasc. Biol. 20 2000 2113 2119